A Pharmacogenomic Research in Korean Populatio
Not Applicable
Completed
- Conditions
- Diseases of the nervous system
- Registration Number
- KCT0000960
- Lead Sponsor
- ational Institute of Food and Drug Safety Evaluation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
CYP2D6 EM (CYP2D6*1/*1 or *1/*2) and CYP2D6 IM (CYP2D6*10/*10)confirmed by pre-genotyping
non-smoker,non-heavy drinker,
not administration of other drugs
healthy volunteers confirmed by physical and laboratory examination
informed consent provided
Exclusion Criteria
smoker or heavy drinker
coadministration of other drugs
not healthy from laboratory or physical examination
informed consent not provided
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method venlafaxine, O-desmethylvenlafaxine plasma concentration
- Secondary Outcome Measures
Name Time Method venlafaxine, O-desmethylvenlafaxine pharmacokinetic parameters